Trial Profile
A Phase III, Randomized Trial of BC 819 in Patients with Bladder Cancer who Failed Initial Treatment with BCG
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms Leo study
- Sponsors Anchiano Therapeutics; Chemomab Therapeutics
- 07 Sep 2018 According to a Anchiano Therapeutics website, Codex study and Leo study will support an application for marketing approval in the US and other countries of inodiftagene vixteplasmid (BC 819) for use in the treatment of bladder cancer.
- 07 Sep 2018 According to a Anchiano Therapeutics website, the company is planning to launch this study in early 2019. (link: https://www.anchiano.com/lead-program/future-development-plan/ )
- 07 Sep 2018 Planned number of patients changed from 470 to 495, according to a Anchiano Therapeutics website.